General Surgery »  Faculty »  Breast Care Surgery »  Laura J. Esserman, M.D., M.B.A.
Laura J. Esserman, M.D., M.B.A.

Laura J. Esserman, M.D., M.B.A.

Professor of Surgery and Radiology
Division of General Surgery
Alfred A. de Lorimier Endowed Chair in General Surgery
Director, UCSF Carol Franc Buck Breast Care Center
Chief, Section of Breast Care Surgery

Contact Information

Open Popup
  • 1974-77, Harvard University, A.B.
  • 1978-83, Stanford University, M.D.
  • 1983-85, Stanford University School of Medicine, Resident, General Surgery
  • 1988-90, Stanford University School of Medicine, Resident, General Surgery
  • 1990-91, Stanford University School of Medicine, Chief Resident, General Surgery
  • 1985-88, Stanford University School of Medicine, Postdoctoral Fe, Oncology, Medical
  • 1991-93, Stanford University, M.B.A.
  • American Board of Surgery - General Surgery - 1992
  • UCSF Center of Excellence for Breast Cancer Care
  • UCSF Carol Frank Buck Breast Care Center
  • UCSF Helen Diller Comprehensive Cancer Center
  • Breast Diseases
  • Breast Neoplasms
  • Cancer Vaccines
  • Genes
  • Intraductal Carcinoma
  • Male
  • Mammary
  • Mastectomy
  • Noninfiltrating Carcinoma Lobular
  • Oncogenes
  • Precancerous Conditions
  • Segmental
  • Tumor Suppressor
  • Ultrasonography
  • BRCA1 Protein
  • BRCA2 Protein
  • Infiltrating Duct Carcinoma

 

Dr. Laura Esserman, M.D., M.B.A is a surgeon and breast cancer oncology specialist practicing at the UCSF Carol Franc Buck Breast Care Center where she has also held the position of Director since 1996.  She co-leads the Breast Oncology Program, the largest of the UCSF Helen Diller Comprehensive Cancer Center's multidisciplinary programs. The program is comprised of 69 faculty members who represent 16 academic specialties and is internationally recognized and well-established with major initiatives in epidemiology, genetics, biology, therapeutics, and clinical cancer care.  She is a professor of Surgery & Radiology at UCSF and Associate Director of the UCSF Helen Diller Family Comprehensive Cancer Center where she has founded and led the program in Translational Informatics. As part of this program, her research has focused on bioinformatics, medical and clinical informatics, systems integration, and clinical care delivery.

 

Dr. Esserman received her Bachelor's degree in History of Science from Harvard University and completed her M.D. at Stanford University. She completed her surgery residency and oncology fellowship at Stanford University Medical Center.  After her training, she joined the faculty at Stanford and received a Hartford fellowship to attend Stanford Business School where she received her M.B.A. in 1993.  She then joined the faculty at the University of California, San Francisco.  She has worked at UCSF to develop interdisciplinary teams of clinicians and researchers to bring the best care to patients and find the best platform to integrate translational research and improve the delivery of breast cancer care.

 

Dr. Esserman has been a leader in the I-SPY TRIAL collaboration, a National Cancer Institute's (NCI) Center for Bioinformatics and SPORE program. In 2005, she received the NCI SPORE Investigator of the Year Award, an internationally recognized honor and designation.  As the Primary Investigator of a Department of Defense-funded Center of Excellence grant, she has also brought together an extraordinary, multidisciplinary group of investigators and health care industry partners to work on critical problems concerning the quality of breast cancer care. Highly respected by her peers, Dr. Esserman was named to the list of U.S. News "America's Top Doctors," a distinction reserved for the top 1% of physicians in the nation for a given specialty.

 

Dr. Esserman is a prolific writer with numerous publications in peer-reviewed journals covering all aspects of breast health including information systems, immunology, decision making, health policy and the use of imaging. She speaks extensively at public and private forums within the U.S. and internationally.  Overall, Dr. Esserman's research and writing tends to focus on the goal of giving patients better access to accurate information so that they can become partners in their health care.

Most recent publications from a total of 270
  1. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107. View in PubMed
  2. van 't Veer LJ, Yau C, Yu NY, Benz CC, Nordenskjöld B, Fornander T, Stål O, Esserman LJ, Lindström LS. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk. Breast Cancer Res Treat. 2017 Aug 04. View in PubMed
  3. Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 Aug; 165(1):161. View in PubMed
  4. Fowble B, Jairam AK, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Park C, Lazar A. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women. Clin Breast Cancer. 2017 Aug 01. View in PubMed
  5. Vidula N, Yau C, Li J, Esserman LJ, Rugo HS. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2017 Aug; 165(1):129-138. View in PubMed
  6. Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A, Chhieng D, Giri D, Livasy C, Mies C, Rabban J, Sarode VR, Singh B, Esserman L, Chen YY. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2017 Aug; 165(1):181-191. View in PubMed
  7. Peled AW, Sears M, Wang F, Foster RD, Alvarado M, Wong J, Ewing CA, Sbitany H, Esserman LJ, Fowble B. Complications After Total Skin-Sparing Mastectomy and Expander-Implant Reconstruction: Effects of Radiation Therapy on the Stages of Reconstruction. Ann Plast Surg. 2017 Jun 01. View in PubMed
  8. Jo Chien A, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 May 13. View in PubMed
  9. Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, Bågeman E, D'Agostino RB, Ver Hoeve ES, Esserman L, Cigler T. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. JAMA. 2017 02 14; 317(6):606-614. View in PubMed
  10. Hosseini A, Khoury AL, Esserman LJ. Precision surgery and avoiding over-treatment. Eur J Surg Oncol. 2017 May; 43(5):938-943. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Laura J. Esserman, M.D., M.B.A.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.
  • Jessica Galloway

    Breast Cancer Turns San Francisco Mom into Advocate

    Jessica Galloway hates to be called a 'cancer survivor.' It's been four years since she began her battle with breast cancer, and she feels healthy and strong, but the thought that her cancer might return is never far from her mind, and she resists the label of conquering hero. "I don't know that I will survive breast cancer," she says. But you could certainly call her a fighter. Once diagnosed, the former competitive ski racer attacked her disease like she might have tackled a ski course: with all the effort she could muster. In addition to[...]
    Story Categories: Breast Cancer

X